Stay updated on iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial
Sign up to get notified when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.

Latest updates to the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page
- Check2 days agoChange DetectedThe website’s displayed revision number changed from v3.8.0 to v3.8.1; the clinical study record remains unchanged.SummaryDifference0.1%

- Check9 days agoChange DetectedThe record presents details of the NIPICOL phase II study of nivolumab and ipilimumab for metastatic colorectal cancer, including its eligibility criteria, treatment plan, outcomes, locations, and study status.SummaryDifference53%

- Check16 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the study record remains unavailable behind a 403 error.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide NIH transition notice appears above the ClinicalTrials.gov page, and the site revision advances from v3.7.1 to v3.7.2. The study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check43 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the previous content. This indicates that access to the page is blocked and the normal study details are not visible.SummaryDifference19%

Stay in the know with updates to iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.